Use

Abstract

Non-therapeutic use of a bioactive substance for mood modulation of a subject, wherein the bioactive substance is one or more of yangonin, α-amyrin, β-amyrin, cyanidin, curcumin, catechin, quercetin,

Description

FIELD OF THE INVENTION The present disclosure relates to non-therapeutic uses of a bioactive substance; a composition comprising the bioactive substance; non-therapeutic methods comprising administering the bioactive substance or composition to a subject; a consumable comprising the bioactive substance or composition; and a delivery system comprising the consumable. BACKGROUND OF THE INVENTION The present disclosure relates to bioactive substances or biologically active ingredients intended for human use and compositions comprising bioactive substances or biologically active ingredients. The wellness industry is growing, with consumers increasingly interested in their overall physical and mental wellbeing and / or performance. Therefore, products that can provide a beneficial effect such as enhancing the wellbeing of an individual, be that through improved health, better sleep, increased mindfulness or other measures of ‘wellness’, have become popular and are of increased commercial importance. Such products may include bioactive ingredients that are delivered to the user in order to cause a biological response in the user that may enhance physical or mental wellbeing and / or performance of the user. Therefore, it would be desirable to provide consumers with non-therapeutic products to modulate mood, enhance performance and / or provide other health benefits such as providing an anti-fatigue effect, restoring balance and increasing adaptability to overcome daily physical and mental challenges. SUMMARY OF THE INVENTION In accordance with some embodiments described herein, there is provided a non-therapeutic use of a bioactive substance for mood modulation of a subject, wherein the bioactive substance is one or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. Suitably, the bioactive substance may improve mood of the subject. The bioactive substance may modulate (e.g. improve) mood by activating the serotonin pathway. The bioactive substance may modulate the mood of the subject by providing the subject with a calming effect. The bioactive substance may modulate the mood of the subject by providing the subject with a stimulating effect. In accordance with some embodiments described herein, there is provided a non-therapeutic use of a bioactive substance, pre-exercise, to reduce muscle and / or mental fatigue in a subject, wherein the bioactive substance is one or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. The use of the bioactive substance may be before exercise. The bioactive substance may be provided in combination with one or more additional active substance(s). In accordance with some embodiments described herein, there is provided a composition comprising the bioactive substance for use in non-therapeutic mood modulation of a subject as described herein, or for use to reduce muscle and / or mental fatigue in a subject as described herein. The composition may additionally comprises at least one additional active substance as defined herein. The composition may additionally comprise one or more flavour(s). The one or more flavour(s) may comprise an aroma. In accordance with some embodiments described herein, there is provided a non-therapeutic method of modulating mood in a subject, wherein said method comprises administering the bioactive substance as described herein or the composition as described herein, to the subject. In accordance with some embodiments described herein, there is provided a non-therapeutic method of reducing muscle and / or mental fatigue of a subject, during or after exercise, comprising administering the bioactive substance as described herein or the composition as described herein. Suitably, the bioactive substance as described herein or the composition as described herein may be administered to the subject before the exercise commences. In accordance with some embodiments described herein, there is provided a consumable comprising the bioactive substance as described herein or the composition as described herein. In accordance with some embodiments described herein, there is provided a delivery system comprising the consumable as described herein. The delivery system may be a non-combustible aerosol provision system, or an aerosol-free delivery system. The delivery system may be a vaping device, home diffuser, car diffuser, wax melt or an inhaler. The delivery system may be an aerosol-free delivery system. The aerosol-free delivery system may be one or more of an edible, a lozenge, a gum, a patch, an inhalable powder, a beverage, a shot, an oil, an ointment, a supplement or an oral product. BRIEF DESCRIPTION OF THE DRAWINGS Embodiments of the invention will now be described by way of example only, with reference to accompanying drawings, in which: Figure 1: (A) Model of quercetin I Cannabinoid type 2 (CB2) receptor binding mode. Quercetin was docked into the CB2 orthosteric pocket using the crystal structure of human G protein coupled receptor Protein Data Bank (PDB) entry 5ZTY) as receptor and a rigid receptor protocol. H-bonds are denoted as yellow dashed lines, pi-pi stacking interactions are denoted as blue dashed lines. (B) Structure of quercetin (C) Structure of AM10257. Figure 2: (A) Model of catechin I CB2 binding mode. Catechin was docked into the CB2 orthosteric pocket using the structure 6PT0 as receptor and a rigid receptor protocol. H-bonds are denoted as dashed lines. (B) Structure of catechin (C) Structure of WIN_55212-2. Figure 3: (A) Model of cyanidin I CB2 binding mode. Cyanidin was docked into the CB2 orthosteric pocket using the structure 6PT0 as receptor and a rigid receptor protocol. H-bonds are denoted as dashed lines. (B) Structure of cyanidin (C) Structure of WIN_55212-2. Figure 4: (A) Model of yangonin I CB2 binding mode. Yangonin was docked into the CB2 orthosteric pocket using the structure 5ZTY as receptor and a rigid receptor protocol. (B) Structure of yangonin (C) Structure of AM10257. Figure 5: The effect of alpha-amyrin, beta-amyrin, catechin, curcumin, cyanidin, quercetin and yangonin compared to CBD and a known agonist (serotonina) on 5HT-1A receptors expressed in a human embryonic kidney (HEK) cell line. (A) shows the results at 100 nM; and (B) at 1 pM; Figure 6: The effect of Catechin (+ / -), curcumin and quercetin on 5HT-1A receptors expressed in a HEK cell line. (A) shows a dose response curve for catechin (+ / -), curcumin and quercetin at 5HT-1A receptors; (B) shows the ECso and maximum response of Catechin (+ / -), curcumin and quercetin at 5HT-1A receptors (* = Versus basal; &= No significant effect). Figure 7: The effect of alpha-amyrin, beta-amyrin, catechin, curcumin, cyanidin, quercetin and yangonin compared to CBD and a known agonist (CP55490) on CB1 receptors expressed in a HEK cell line. (A) shows the results at 100 nM; and (B) at 1 pM. Figure 8: The effect of Catechin (+ / -), curcumin and quercetin on CB1 receptors expressed in a HEK cell line. (A) shows a dose response curve for catechin (+ / -), curcumin and quercetin at CB1 receptors; (B) shows the ECso and maximum response of Catechin (+ / -), curcumin and quercetin at CB1 receptors. (* = Versus basal; &= No significant effect). Figure 9: The effect of alpha-amyrin, beta-amyrin, catechin, curcumin, cyanidin, quercetin and yangonin compared to CBD and a known agonist (JWH-133) on CB2 receptors expressed in a HEK cell line. (A) shows the results at 100 nM; and (B) at 1 pM. Figure 10: The effect of Catechin (+ / -), curcumin and quercetin on CB2 receptors expressed in a HEK cell line. (A) shows a dose response curve for catechin (+ / -), curcumin and quercetin at CB2 receptors; (B) shows the ECso and maximum response of Catechin (+ / -), curcumin and quercetin at CB2 receptors. (* = Versus basal; &= No significant effect). Figure 11: The effect of Catechin (+ / -) and curcumin on Angiotensin 1 (AT1) receptors expressed in a HEK cell line. (A) shows a dose response curve for catechin (+ / -) and curcumin at AT 1 receptors; (B) shows the ECso and maximum response of Catechin (+ / -) and curcumin at AT 1 receptors. (* = Versus basal; &= No significant effect). DEFINITIONS This disclosure is not limited by the exemplary methods and materials disclosed herein, and any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of this disclosure. The headings provided herein are not limitations of the various aspects or embodiments of this disclosure which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification as a whole. As used herein, “bioactive substance” refers to one or more compounds that has an effect on a living organism, tissue or cell. The “bioactive substance” may be derived from plants, animals, or animal products. The “bioactive substance” may also be synthetic. As used herein, “synthetic” refers to ‘man-made’ compounds, e.g. those synthesised by in vitro methods. However, “synthetic” compounds may also include “biosynthetic” compounds, for example compounds that are produced in a living organism, or a laboratory process modelled after the synthesis pathway in a living organism. “Biosynthetic” compounds may include those compounds that are produced by or in, for example, a plant, bacteria, fungi, etc., e.g. following genetic engineering to insert the relevant gene(s) to result in the expression of the desired synthetic compound. As used herein, “subject” refers to the recipient of the bioactive substance. The “subject” may be human or animal. In some embodiments, the subject is human. In some embodiments, the subject is an animal. Where the subject is an animal, the animal may be mammalian, avian, reptilian, amphibian, invertebrate or aquatic (fish). Where the animal is a mammalian animal, the mammalian animal may be a monotreme (such as a platypus or echidna), marsupial (such as a kangaroo, wallaby, wambat, etc.), or a placental mammal (such as a primate - monkeys, apes; canine - dogs, wolves, foxes, etc.; feline - domestic cats, lions, tigers, etc.) As used herein, “calming” refers to the state of being soothed, pacified, placated, sedate, tranquil, content, satisfied, comfortable, serene, composed, unwound, relaxed, rejuvenated, or other similar terms. The feeling of “calm” is unique to each subject. Thus, a subject is considered to have achieved a feeling of “calm” if they feel any reduction in tension, agitation, nervousness, frustration, anger, anxiousness, upset, distress, worry, unrest, apprehension, vexation, fear, stress, or similar negative moods or emotions. As used herein, “stimulating” refers to the state of being revitalised, revived, refreshed, uplifted, invigorated, boosted, aroused, elevated or other similar terms. The feeling of “stimulation” is unique to each subject. Thus, a subject is considered to have achieved a feeling of “stimulation” if they feel any increase in energy, motivation, drive, enthusiasm, or similar positive moods or emotions or a decrease in apathy, lethargy, or similar negative moods or emotions. As used herein, “fatigue” refers to muscle and / or mental fatigue. The state of “muscle fatigue” refers to the feeling of weakness in the muscle following exertion. Other symptoms of muscle fatigue may include soreness, localised pain, muscle twitching, trembling, a weak grip and muscle cramps. The state of “mental fatigue” refers to exhaustion, burnout, feeling drained, tiredness, reduction in concentration, or other similar terms. The feeling of “muscle fatigue” and “mental fatigue” is unique to each subject. Thus, a subject is considered to have achieved a reduction in “muscle fatigue” and / or mental fatigue, if they feel a reduction in any of the listed symptoms compared to how they would feel following exercise without having taken the bioactive substance. For example, the subject may experience a feeling of being restored, refilled, energised, rebalanced, refreshed, recovered or recharged, or other similar terms. As used herein, “anxiolytic active” refers to an active which has the general effect of reducing anxiety and / or stress. As used herein, “ergogenic active” refers to an active which enhances performance, especially physical performance and athleticism i.e. is energy-giving. As used herein, “nootropic active” refers to an active which improves cognitive function such as memory, creativity and attention, i.e. is cognitive-enhancing. As used herein, “relaxant active” refers to an active which has a calming or relaxing but not sedative effect. As used herein, the terms "flavour" and "flavourant" refer to materials which, where local regulations permit, may be used to create a desired taste, aroma or other somatosensorial sensation in a product for adult consumers. They may include naturally occurring flavour materials, botanicals, extracts of botanicals, synthetically obtained materials, or combinations thereof (e.g., tobacco, cannabis, licorice (liquorice), hydrangea, eugenol, Japanese white bark magnolia leaf, chamomile, fenugreek, clove, maple, matcha, menthol, Japanese mint, aniseed (anise), cinnamon, turmeric, Indian spices, Asian spices, herb, wintergreen, cherry, berry, red berry, cranberry, peach, apple, orange, mango, clementine, lemon, lime, tropical fruit, papaya, rhubarb, grape, durian, dragon fruit, cucumber, blueberry, mulberry, citrus fruits, Drambuie, bourbon, scotch, whiskey, gin, tequila, rum, spearmint, peppermint, lavender, aloe vera, cardamom, celery, cascarilla, nutmeg, sandalwood, bergamot, geranium, khat, naswar, betel, shisha, pine, honey essence, rose oil, vanilla, lemon oil, orange oil, orange blossom, cherry blossom, cassia, caraway, cognacjasmine, ylang-ylang, sage, fennel, wasabi, piment, ginger, coriander, coffee, hemp, a mint oil from any species of the genus Mentha, eucalyptus, star anise, cocoa, lemongrass, rooibos, flax, ginkgo biloba, hazel, hibiscus, laurel, mate, orange skin, rose, tea such as green tea or black tea, thyme, juniper, elderflower, basil, bay leaves, cumin, oregano, paprika, rosemary, saffron, lemon peel, mint, beefsteak plant, curcuma, cilantro, myrtle, cassis, valerian, pimento, mace, damien, marjoram, olive, lemon balm, lemon basil, chive, carvi, verbena, tarragon, limonene, thymol, camphene), flavour enhancers, bitterness receptor site blockers, sensorial receptor site activators or stimulators, sugars and / or sugar substitutes (e.g., sucralose, acesulfame potassium, aspartame, saccharine, cyclamates, lactose, sucrose, glucose, fructose, sorbitol, or mannitol), and other additives such as charcoal, chlorophyll, minerals, botanicals, or breath freshening agents. They may be imitation, synthetic or natural ingredients or blends thereof. They may be in any suitable form, for example, liquid such as an oil, solid such as a powder, or gas. Other definitions of terms may appear throughout the specification. Before the exemplary aspects and embodiments are described in more detail, it is important to understand that this disclosure is not limited to particular aspects or embodiments described, which as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects or embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims. It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a bioactive substance” or “a flavour” includes a plurality of such candidate agents and equivalents thereof known to those skilled in the art, and so forth. DETAILED DESCRIPTION OF THE INVENTION In one aspect, there is provided a non-therapeutic use of a bioactive substance for mood modulation of a subject, wherein the bioactive substance is one or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In one embodiment, the bioactive substance is two or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In one embodiment, the bioactive substance is three or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In one embodiment, the bioactive substance is four or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In one embodiment, the bioactive substance is five or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin andsalvinorin A. In one embodiment, the bioactive substance is six or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In one embodiment, the bioactive substance is seven or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In one embodiment, the bioactive substance is yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In an embodiment, the bioactive substance is yangonin. In an embodiment, the bioactive substance is a-amyrin. In an embodiment, the bioactive substance is p-amyrin. In an embodiment, the bioactive substance is cyanidin. In an embodiment, the bioactive substance is curcumin. In an embodiment, the bioactive substance is catechin. In an embodiment, the bioactive substance is quercetin. In an embodiment, the bioactive substance is salvinorin A. The skilled person will understand that stereoisomers of the bioactive substances, disclosed herein, may exist and may exert different actions on the subject. Therefore, references to the bioactive substance may encompass both the cis and trans form of the named bioactive substance. For example, in one embodiment, catechin is (+)-catechin or (-)-catechin. In a further embodiment, catechin is (+)-catechin. In a further embodiment, catechin is (-)-catechin. In an embodiment, the bioactive substance modulates mood by activating the serotonin pathway. In an embodiment, the mood modulation of the subject is calming or stimulating. In an embodiment, the mood modulation of the subject is calming. In an embodiment, the mood modulation of the subject is stimulating. In one embodiment the bioactive substance is an anxiolytic active. In one embodiment the bioactive substance is an ergogenic active. In one embodiment the bioactive substance is a nootropic active. In one embodiment the bioactive substance is a relaxant active. In one aspect, there is provided a non-therapeutic use of a bioactive substance to reduce exercise induced muscle and / or mental fatigue in a subject, wherein the bioactive substance is one or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In an embodiment, there is provided a non-therapeutic use of a bioactive substance to reduce exercise induced muscle fatigue in a subject, wherein the bioactive substance is one or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In an embodiment, there is provided a non-therapeutic use of a bioactive substance to reduce exercise induced mental fatigue in a subject, wherein the bioactive substance is one or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In one embodiment, the bioactive substance is two or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In one embodiment, the bioactive substance is three or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In one embodiment, the bioactive substance is four or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In one embodiment, the bioactive substance is five or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In one embodiment, the bioactive substance is six or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In one embodiment, the bioactive substance is seven or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In one embodiment, the bioactive substance is yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In an embodiment, the bioactive substance is yangonin. In an embodiment, the bioactive substance is a-amyrin. In an embodiment, the bioactive substance is p-amyrin. In an embodiment, the bioactive substance is cyanidin. In an embodiment, the bioactive substance is curcumin. In an embodiment, the bioactive substance is catechin. In an embodiment, the bioactive substance is quercetin. In an embodiment, the bioactive substance is salvinorin A. In one embodiment, catechin is (+)-catechin or (-)-catechin. In a further embodiment, catechin is (+)-catechin. In a further embodiment, catechin is (-)-catechin. In an embodiment, the use of the bioactive substance is before exercise. In an embodiment, the bioactive substance described herein is provided in combination with one or more additional active substance(s). In an embodiment, the bioactive substance described herein is provided in combination with two or more additional active substance(s). In an embodiment, the bioactive substance described herein is provided in combination with three or more additional active substance(s). In an embodiment, the bioactive substance described herein is provided in combination with four or more additional active substance(s). In an embodiment, the bioactive substance described herein is provided in combination with five, six, seven, eight, nine, ten or more additional active substance(s). The additional active substance may be any substance that elicits a desired effect on the subject. The desired effect produced by the bioactive substance in combination with one or more additional active substance(s) may be calming, stimulating, or reducing muscle and / or mental fatigue. The bioactive substance in combination with one or more additional active substance(s) provides a calming effect. The bioactive substance in combination with one or more additional active substance(s) provides a stimulating effect. The bioactive substance in combination with one or more additional active substance(s) reduces muscle fatigue. The bioactive substance in combination with one or more additional active substance(s) reduces mental fatigue. Alternatively, the additional bioactive substance may produce an additional desired effect that is different to the desired effect produced by the bioactive substance. The additional desired effect may be complementary to the desired effect produced by the bioactive substance. In instances where multiple additional active substances are provided, multiple different additional desired effects may be achieved. These effects may be complimentary to the desired effect produced by the bioactive substance. In a further embodiment, the additional active substance potentiates the effect of the bioactive substance. In a further embodiment, the additional active substance potentiates the effect of the bioactive substance and produces an additional effect to the effect produced by the bioactive substance. In a further embodiment, the additional active substance produces an additional effect to the effect produced by the bioactive substance. Composition In one aspect, there is provided a composition comprising the bioactive substance for use in non-therapeutic mood modulation of a subject as described herein, or for use to reduce exercise induced muscle and / or mental fatigue in a subject as described herein. In one embodiment, the bioactive substance is one or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In one embodiment, the bioactive substance is two or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In one embodiment, the bioactive substance is three or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin, salvinorin A. In one embodiment, the bioactive substance is four or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In one embodiment, the bioactive substance is five or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In one embodiment, the bioactive substance is six or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In one embodiment, the bioactive substance is seven or more of the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In one embodiment, the bioactive substance is yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A. In an embodiment, the bioactive substance is yangonin. In an embodiment, the bioactive substance is a-amyrin. In an embodiment, the bioactive substance is p-amyrin. In an embodiment, the bioactive substance is cyanidin. In an embodiment, the bioactive substance is curcumin. In an embodiment, the bioactive substance is catechin. In an embodiment, the bioactive substance is quercetin. In an embodiment, the bioactive substance is salvinorin A. In one embodiment, catechin is (+)-catechin or (-)-catechin. In a further embodiment, catechin is (+)-catechin. In a further embodiment, catechin is (-)-catechin. In an embodiment, the composition additionally comprises an additional active substance as disclosed herein. In an embodiment, the composition additionally comprises one or more flavours. In an embodiment, the flavour comprises menthol, spearmint and / or peppermint. In an embodiment, the flavour comprises flavour components of cucumber, blueberry, citrus fruits and / or redberry. In an embodiment, the flavour comprises eugenol. In an embodiment, the flavour comprises flavour components extracted from tobacco. In an embodiment, the flavour comprises flavour components extracted from cannabis. In an embodiment, the flavour may comprise a sensate, which is intended to achieve a somatosensorial sensation which are usually chemically induced and perceived by the stimulation of the fifth cranial nerve (trigeminal nerve), in addition to or in place of aroma or taste nerves, and these may include agents providing heating, cooling, tingling, numbing effect. A suitable heat effect agent may be, but is not limited to, vanillyl ethyl ether and a suitable cooling agent may be, but not alimited to eucolyptol, WS-3. In a further embodiment, the one or more flavours comprises an aroma. In an embodiment, the composition comprises: i) one or more bioactive substance selected from the group comprising or consisting of yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin, salvinorin A; ii) one or more additional active substance(s); and optionally iii) one or more flavours as disclosed herein. Method In one aspect, there is provided a non-therapeutic method of modulating mood in a subject, wherein said method comprises administering the bioactive substance as described herein or the composition as described herein, to the subject. In one aspect, there is provided a non-therapeutic method of reducing muscle and / or mental fatigue of a subject, during or after exercise, comprising administering the bioactive substance as disclosed herein or the composition as disclosed herein, to the subject before the exercise commences. The subject is a healthy individual. For example the subject has not been diagnosed with any disease, medical condition, or deficiency. Consumable In one aspect, there is provided a consumable comprising the bioactive substance as described herein or the composition as described herein. A consumable is an article comprising or consisting of aerosol-generating material, part or all of which is intended to be consumed during use by a user. A consumable may comprise one or more other components, such as an aerosol-generating material storage area, an aerosolgenerating material transfer component, an aerosol generation area, a housing, a wrapper, a mouthpiece, a filter and / or an aerosol-modifying agent. A consumable may also comprise an aerosol generator, such as a heater, that emits heat to cause the aerosol-generating material to generate aerosol in use. The heater may, for example, comprise combustible material, a material heatable by electrical conduction, or a susceptor. A consumable may also be an article that does not comprise an aerosol-generating material. Instead, the consumable comprises an article, part or all of which is intended to be consumed during use by a user, such as gums, patches, or inhalable powders. Delivery system In one aspect, there is provided a delivery system comprising the consumable as disclosed herein. As used herein, the term “delivery system” is intended to encompass systems that deliver at least one substance to a user, and includes: non-combustible aerosol provision systems that release compounds from an aerosolgenerating material without combusting the aerosol-generating material, such as electronic cigarettes, tobacco heating products, and hybrid systems to generate aerosol using a combination of aerosol-generating materials; and aerosol-free delivery systems that deliver the at least one substance to a user orally, nasally, transdermally or in another way without forming an aerosol, including but not limited to, lozenges, gums, patches, articles comprising inhalable powders, and oral products such as snus or moist snuff. In an embodiment, the delivery system is a non-combustible aerosol provision system, or an aerosol-free delivery system. According to the present disclosure, a “non-combustible” aerosol provision system is one where a constituent aerosol-generating material of the aerosol provision system (or component thereof) is not combusted or burned in order to facilitate delivery of at least one substance to a user. In an embodiment, the delivery system is a non-combustible aerosol provision system, such as a powered non-combustible aerosol provision system. In an embodiment, the non-combustible aerosol provision system is an electronic cigarette, also known as a vaping device or electronic nicotine delivery system (END), although it is noted that the presence of nicotine in the aerosol-generating material is not a requirement. In an embodiment, the non-combustible aerosol provision system is an aerosolgenerating material heating system, also known as a heat-not-burn system. An example of such a system is a tobacco heating system, although it is noted that the presence of tobacco in the heat-not-burn system is not a requirement. In an embodiment, the non-combustible aerosol provision system is a hybrid system to generate aerosol using a combination of aerosol-generating materials, one or a plurality of which may be heated. Each of the aerosol-generating materials may be, for example, in the form of a solid, liquid or gel. In some embodiments, the hybrid system comprises a liquid or gel aerosol-generating material and a solid aerosol-generating material. The solid aerosol-generating material may comprise, for example, tobacco or a non-tobacco product. Typically, the non-combustible aerosol provision system may comprise a non-combustible aerosol provision device and a consumable for use with the non-combustible aerosol provision device. In an embodiment, the consumable for use with the non-combustible aerosol provision device is a consumable as disclosed herein. In an embodiment, the disclosure relates to consumables comprising aerosol-generating material and the composition as disclosed herein, configured to be used with non-combustible aerosol provision devices. These consumables are sometimes referred to as articles throughout the disclosure. In an embodiment, the non-combustible aerosol provision system, such as a non-combustible aerosol provision device thereof, may comprise a power source and a controller. The power source may, for example, be an electric power source or an exothermic power source. In some embodiments, the exothermic power source comprises a carbon substrate which may be energised so as to distribute power in the form of heat to an aerosol-generating material or to a heat transfer material in proximity to the exothermic power source. In an embodiment, the non-combustible aerosol provision system may comprise an area for receiving the consumable, an aerosol generator, an aerosol generation area, a housing, a mouthpiece, a filter and / or an aerosol-modifying agent. In an embodiment, the consumable for use with the non-combustible aerosol provision device may comprise aerosol-generating material and the composition as disclosed herein, an aerosol-generating material storage area, an aerosol-generating material transfer component, an aerosol generator, an aerosol generation area, a housing, a wrapper, a filter, a mouthpiece, and / or an aerosol-modifying agent. In an embodiment, the delivery system is a non-combustible aerosol provision system. In a further embodiment, the non-combustible aerosol provision system is one or more of the group comprising or consisting of a vaping device, home diffuser, car diffuser, wax melt or an inhaler. In yet a further embodiment, the inhaler is a metered dose inhaler, a dry powder inhaler, or a soft mist inhaler. In an embodiment, the delivery system is an aerosol-free delivery system. In an embodiment, the delivery system is an aerosol-free delivery system that delivers at least one substance to a user orally, nasally, transdermally or in another way without forming an aerosol, including but not limited to, lozenges, gums, patches, articles comprising inhalable powders, and oral products such as snus or moist snuff. Whilst snus or moist snuff are traditionally tobacco products, the contents of the snus pouch or snuff may be something other than tobacco. In a further embodiment, the aerosol-free delivery system is an edible, a lozenge, a gum, a patch, an inhalable powder, a beverage, a shot, an oil, an ointment, a supplement or an oral product. The various embodiments described herein are presented only to assist in understanding and teaching the claimed features. These embodiments are provided as a representative sample of embodiments only, and are not exhaustive and / or exclusive. It is to be understood that advantages, embodiments, examples, functions, features, structures, and / or other aspects described herein are not to be considered limitations on the scope of the invention as defined by the claims or limitations on equivalents to the claims, and that other embodiments may be utilised and modifications may be made without departing from the scope of the claimed invention. Various embodiments of the invention may suitably comprise, consist of, or consist essentially of, appropriate combinations of the disclosed elements, components, features, parts, steps, means, etc., other than those specifically described herein. In addition, this disclosure may include other inventions not presently claimed, but which may be claimed in future. The invention will now be described with reference to the following non-limiting examples. EXAMPLES Example 1: Binding Mode Analysis of the bioactive at the CB2 receptor Binding mode analysis was carried out for quercetin, catechin, cyanidin, and yangonin at the orthosteric binding pocket of the CB2 receptor. Models of the docking can be seen in Figures 1-4. Quercetin Quercetin was docked into the CB2 orthosteric pocket using the structure 5ZTY as receptor and a rigid receptor protocol. The docking score was -8.2. The binding mode of quercetin is similar to that of catechin and cyanidin. Quercetin is well buried in the CB2 orthosteric pocket, occupying a similar position to the ligand AM 10257 from the structure 5ZTY. Catechin Catechin was docked into the CB2 orthosteric pocket using the structure 6PT0 as receptor and a rigid receptor protocol. The docking score was -9.4. The binding mode of catechin is similar to that of cyanidin and quercetin. Catechin is well buried in the CB2 orthosteric pocket, occupying a similar position to the ligand WIN_55212-2 from the structure 6PTO. Cyanidin Cyanidin was docked into the CB2 orthosteric pocket using the structure 6PT0 as receptor and a rigid receptor protocol. The docking score was -9.2. The binding more of cyanidin is similar to that of catechin and quercetin. Cyanidin is well buried in the CB2 orthosteric pocket, occupying a similar position to the ligand WIN_55212-2 from the structure 6PTO. Yangonin Yangonin was docked into the CB2 orthosteric pocket using the structure 5ZTY as receptor and a rigid receptor protocol. The docking score was -7.0. Yangonin is well buried in the CB2 orthosteric pocket, occupying a similar position to the ligand AM 10257 from the structure 5ZTY. It is reported as a human CB1 binder (Ki = 0.72 pM) with selectivity vs. CB2 (Ki >10 pM) Example 2: MAPK signalling pathway activation by the bioactive MAPK signalling pathway activation is measured by the degree of ERK1 / 2 phosphorylation. The heterologous expression system consists of HEK-293T cells expressing the human version of the G protein-coupled receptors (GPCRs) that are tested. To avoid reliability issues due to the use of Western blot for measuring pERK versus total ERK phosphorylation, a Perkin Elmer proprietary method is used. It consists of the AlphaScreen®SureFire® kit (Perkin Elmer, Wellesley, USA). Cultured cells are placed in 96-well plates in non-supplemented medium two hours before starting the incubation with the different compounds. For the agonistic assay type, compounds were added 7 minutes before agonist removal and cell lysis (see below for details when assaying allosteric potential). Cells were washed twice with cold PBS before the addition of 30 pl / well “Ultra lysis buffer” -PerkinElmer- (15 min treatment). Afterwards, 10 pl of each supernatant were placed in white ProxiPlate 384-well plates and ERK1 / 2 phosphorylation was determined using an AlphaScreen®SureFire® kit (PerkinElmer), following the instructions of the supplier, and using an EnSpire® Multimode Plate Reader (PerkinElmer, Waltham, MA, USA). The reference value (100%) was the value achieved in the absence of any treatment (basal). Agonist effects were given in percentage with respect to the basal value. Allosteric potential Allosteric potential was assayed using 100 nM of the compound 15 minutes before adding a selective agonist of the tested receptor. EC50 calculation Dose response curves were obtained using compounds in concentrations ranging from 10 nM to 10 pM. Values are given in percentage considering that 100% was the basal level of phosphorylation. IC50 values were obtained by non-linear regression using the following equation Max — Min Y = Min -I-- 1 ( X / £’C50)H‘" coefficient Concentration is in the X axis and the effect (percentage) is in the Y axis. The percentage of ERK1 / 2 phosphorylation is given respect to the basal value in the absence of any compound (100), therefore, MIN=100. Calculated MAX is the maximal degree of phosphorylation, i.e. the maximal effect of a given compound. Hill coefficient value is fixed to 1. The effect of the compounds was screened against human receptors 5HT-1A (Serotonin 1A), Cannabinoid Receptor 1 (CB1), Cannabinoid Receptor 2 (CB2), and Angiotensin 1 receptor (AT1) expressed in the HEK cell line. Of note is the effect of Catechin (+ / -), Curcumin and Quercetin on these particular receptors. Both (+)- and (-)-catechin were confirmed to interact with the 5HT-1A receptor, demonstrating an increasing level of ERK1 / 2 phosphorylation as the concentration of (+)- and (-)-catechin increased. At the CB1 receptor (+)-catechin and curcumin generated the greatest level of ERK1 / 2 phosphorylation, suggesting interaction with this receptor. Finally, Quercetin is confirmed to interact with the CB2 receptor in vitro, as identified by the 3D molecular docking screening. Both (+)- and (-)-catechin and curcumin also increased phosphorylation suggesting that these compounds also interact with CB2. Results of the analysis are displayed in Figures 5-11. Example 3: ADMET prediction data for the bioactives Absorption, Distribution, Metabolism, Excretion and Toxicity predictions were analysed for curcumin, yangonin, alpha-amyrin, beta-amyrin, quercetin, +-catechin, - -catechin, cyanidin and Salvinorin A. CBD and TCBD were analysed for comparison. Results of the predicted pharmacokinetics are summarised in Table 1 below. Curcumin Yangonin Alpha-amyrin Beta-amyrin Quercetin + Catechin Catechin Cyanidin Salvinorin A CBD TCBD Solubility class ESOL Soluble Soluble Poor Poor Soluble Soluble Soluble Soluble Soluble Moderate Moderate Ali Moderate Soluble Poor Poor Soluble Soluble Soluble Soluble Moderate Poor Poor Silicos- IT Moderate Moderate Poor Poor Soluble Soluble Soluble Soluble Moderate Moderate Moderate Gl absorption High High Low Low High High High High High High High BBB permeant No Yes No No No No No No No Yes Yes Pgp substrate No No No No No Yes Yes Yes No No No CYP1A2 inhibitor No Yes No No Yes No No Yes No No No CYP2C19 inhibitor No Yes No No No No No No No Yes Yes CYP2C9 inhibitor Yes Yes No No No No No No No Yes Yes CYP2D6 inhibitor No No No No Yes No No No No Yes Yes CYP3A4 inhibitor Yes No No No Yes No No No No Yes Yes Log Kp [cm / s] -6.28 -5.94 -2.51 -2.41 -7.05 -7.82 -7.82 -7.51 -7.16 -3.59 -3.59 Table 1: ADMET predictions

Claims

1. Non-therapeutic use of a bioactive substance for mood modulation of a subject, wherein the bioactive substance is one or more of the group comprising yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin, and salvinorin A.

2. The bioactive substance according to claim 1, wherein the bioactive substance modulates mood by activating the serotonin pathway.

3. The bioactive substance according to claim 1 or claim 2, wherein the mood modulation of the subject is calming or stimulating.

4. Non-therapeutic use of a bioactive substance to reduce exercise induced muscle and / or mental fatigue in a subject, wherein the bioactive substance is one or more of the group comprising yangonin, a-amyrin, p-amyrin, cyanidin, curcumin, catechin, quercetin and salvinorin A.

5. The non-therapeutic use according to claim 4, wherein the use of the bioactive substance is before exercise.

6. The bioactive substance according to any one of claims 1-5, provided in combination with one or more additional active substance(s).

7. A composition comprising the bioactive substance for use in non-therapeutic mood modulation of a subject according to any one of claims 1-3, or for use to reduce exercise induced muscle and / or mental fatigue in a subject according to claim 4 or claim 5.

8. The composition according to claim 7, wherein the composition additionally comprises at least one additional active substance.

9. The composition according to claim 7 or claim 8, wherein the composition additionally comprises one or more flavours.

10. The composition according to claim 9, wherein the one or more flavours comprises anaroma.

11. A non-therapeutic method of modulating mood in a subject, wherein said method comprises administering the bioactive substance according to any one of claims 1-3 or 6 or the composition according to any one of claims 7-10, to the subject.

12. A non-therapeutic method of reducing muscle and / or mental fatigue of a subject, during or after exercise, comprising administering the bioactive substance according to any one of claims 4-6 or the composition according to any one of claims 7-10, to the subject.

13. The non-therapeutic method according to claim 12, wherein said bioactive substance or composition is administered to the subject before the exercise commences.

14. A consumable comprising the bioactive substance according to any one of claims 1-6 or the composition according to any one of claims 7-10.

15. A delivery system comprising the consumable according to claim 14.

16. The delivery system according to claim 15, wherein the delivery system is a noncombustible aerosol provision system, or an aerosol-free delivery system.

17. The delivery system according to claim 15 or claim 16, wherein the delivery system is a vaping device, home diffuser, car diffuser, wax melt or an inhaler.

18. The delivery system according to claim 16, wherein the delivery system is an aerosol-free delivery system.

19. The delivery system according to claim 18, wherein the aerosol-free delivery system is one or more of an edible, a lozenge, a gum, a patch, an inhalable powder, a beverage, a shot, an oil, an ointment, a supplement or an oral product.

Images